Logo image of FENC

FENNEC PHARMACEUTICALS INC (FENC) Stock Fundamental Analysis

NASDAQ:FENC - Nasdaq - CA31447P1009 - Common Stock - Currency: USD

6.88  +0.07 (+1.03%)

After market: 6.88 0 (0%)

Fundamental Rating

4

FENC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While FENC seems to be doing ok healthwise, there are quite some concerns on its profitability. FENC is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year FENC has reported negative net income.
In the past year FENC had a positive cash flow from operations.
FENC had negative earnings in each of the past 5 years.
FENC had a negative operating cash flow in each of the past 5 years.
FENC Yearly Net Income VS EBIT VS OCF VS FCFFENC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -1.92%, FENC belongs to the top of the industry, outperforming 90.73% of the companies in the same industry.
FENC has a better Return On Invested Capital (2.58%) than 93.53% of its industry peers.
Industry RankSector Rank
ROA -1.92%
ROE N/A
ROIC 2.58%
ROA(3y)-75.05%
ROA(5y)-74.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FENC Yearly ROA, ROE, ROICFENC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 600 800

1.3 Margins

FENC's Operating Margin of 3.41% is amongst the best of the industry. FENC outperforms 93.36% of its industry peers.
Looking at the Gross Margin, with a value of 93.52%, FENC belongs to the top of the industry, outperforming 94.06% of the companies in the same industry.
Industry RankSector Rank
OM 3.41%
PM (TTM) N/A
GM 93.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FENC Yearly Profit, Operating, Gross MarginsFENC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, FENC has more shares outstanding
FENC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for FENC is higher compared to a year ago.
FENC Yearly Shares OutstandingFENC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
FENC Yearly Total Debt VS Total AssetsFENC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -1.44, we must say that FENC is in the distress zone and has some risk of bankruptcy.
FENC has a Altman-Z score (-1.44) which is comparable to the rest of the industry.
The Debt to FCF ratio of FENC is 1.27, which is an excellent value as it means it would take FENC, only 1.27 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of FENC (1.27) is better than 95.45% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.27
Altman-Z -1.44
ROIC/WACCN/A
WACCN/A
FENC Yearly LT Debt VS Equity VS FCFFENC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

FENC has a Current Ratio of 7.80. This indicates that FENC is financially healthy and has no problem in meeting its short term obligations.
FENC has a better Current ratio (7.80) than 72.55% of its industry peers.
FENC has a Quick Ratio of 7.64. This indicates that FENC is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of FENC (7.64) is better than 72.20% of its industry peers.
Industry RankSector Rank
Current Ratio 7.8
Quick Ratio 7.64
FENC Yearly Current Assets VS Current LiabilitesFENC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

7

3. Growth

3.1 Past

FENC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.81%, which is quite impressive.
The Revenue has grown by 277.57% in the past year. This is a very strong growth!
Measured over the past years, FENC shows a very strong growth in Revenue. The Revenue has been growing by 400.02% on average per year.
EPS 1Y (TTM)94.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)277.57%
Revenue growth 3Y400.02%
Revenue growth 5YN/A
Sales Q2Q%12.77%

3.2 Future

FENC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.56% yearly.
Based on estimates for the next years, FENC will show a very strong growth in Revenue. The Revenue will grow by 43.91% on average per year.
EPS Next Y137.46%
EPS Next 2Y51.14%
EPS Next 3Y63.82%
EPS Next 5Y40.56%
Revenue Next Year179.16%
Revenue Next 2Y72.58%
Revenue Next 3Y69.4%
Revenue Next 5Y43.91%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
FENC Yearly Revenue VS EstimatesFENC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M
FENC Yearly EPS VS EstimatesFENC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 2 3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

FENC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 39.68 indicates a quite expensive valuation of FENC.
Compared to the rest of the industry, the Price/Forward Earnings ratio of FENC indicates a rather cheap valuation: FENC is cheaper than 92.48% of the companies listed in the same industry.
FENC's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.10.
Industry RankSector Rank
PE N/A
Fwd PE 39.68
FENC Price Earnings VS Forward Price EarningsFENC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

FENC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. FENC is cheaper than 98.60% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.03
EV/EBITDA N/A
FENC Per share dataFENC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
FENC's earnings are expected to grow with 63.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.14%
EPS Next 3Y63.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FENC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FENNEC PHARMACEUTICALS INC

NASDAQ:FENC (3/7/2025, 8:25:12 PM)

After market: 6.88 0 (0%)

6.88

+0.07 (+1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-10 2025-03-10/amc
Inst Owners58.82%
Inst Owner Change7.48%
Ins Owners1.74%
Ins Owner Change0.27%
Market Cap189.41M
Analysts85.45
Price Target13.87 (101.6%)
Short Float %8.85%
Short Ratio33.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-334.04%
Min EPS beat(2)-539.32%
Max EPS beat(2)-128.76%
EPS beat(4)1
Avg EPS beat(4)-248.1%
Min EPS beat(4)-539.32%
Max EPS beat(4)75.87%
EPS beat(8)3
Avg EPS beat(8)-123.11%
EPS beat(12)4
Avg EPS beat(12)-100.84%
EPS beat(16)7
Avg EPS beat(16)-73.96%
Revenue beat(2)0
Avg Revenue beat(2)-29.72%
Min Revenue beat(2)-35.56%
Max Revenue beat(2)-23.88%
Revenue beat(4)2
Avg Revenue beat(4)-4.39%
Min Revenue beat(4)-35.56%
Max Revenue beat(4)31.8%
Revenue beat(8)4
Avg Revenue beat(8)9.38%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4884.98%
EPS NY rev (1m)0%
EPS NY rev (3m)253.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)120.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)36.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 39.68
P/S 3.84
P/FCF 8.03
P/OCF 8.03
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)0.17
Fwd EY2.52%
FCF(TTM)0.86
FCFY12.46%
OCF(TTM)0.86
OCFY12.46%
SpS1.79
BVpS-0.19
TBVpS-0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.92%
ROE N/A
ROCE 3.27%
ROIC 2.58%
ROICexc 11.91%
ROICexgc 11.91%
OM 3.41%
PM (TTM) N/A
GM 93.52%
FCFM 47.81%
ROA(3y)-75.05%
ROA(5y)-74.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.27
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.8
Quick Ratio 7.64
Altman-Z -1.44
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y137.46%
EPS Next 2Y51.14%
EPS Next 3Y63.82%
EPS Next 5Y40.56%
Revenue 1Y (TTM)277.57%
Revenue growth 3Y400.02%
Revenue growth 5YN/A
Sales Q2Q%12.77%
Revenue Next Year179.16%
Revenue Next 2Y72.58%
Revenue Next 3Y69.4%
Revenue Next 5Y43.91%
EBIT growth 1Y109.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year163.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y262.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y262.7%
OCF growth 3YN/A
OCF growth 5YN/A